Characterization of vanadate-based transition-state-analogue complexes of phosphoglucomutase by spectral and NMR techniques.
Near ultraviolet spectral studies were conducted on two inhibitor complexes obtained by treating the dephospho form of the phosphoglucomutase.Mg2+ complex with inorganic vanadate in the presence of either glucose 1-phosphate [cf. Percival, M. D., Doherty, K., & Gresser, M. J. (1990) Biochemistry (first of four papers in this issue)] or glucose 6-phosphate. Part of the spectral differences between the two inhibitor complexes arises because the glucose phosphate moiety in the complex derived from glucose 1-phosphate binds to the enzyme in a different way from the glucose phosphate moiety in the complex derived from glucose 6-phosphate and because these alternative binding modes produce different environmental effects on the aromatic chromophores of the dephospho enzyme. These spectral differences are strikingly similar to those induced by the binding of glucose 1-phosphate and glucose 6-phosphate to the phospho enzyme--which shows that the glucose 1-phosphate and glucose 6-phosphate moieties occupy positions in the inhibitor complexes closely related to those that they occupy in their respective catalytically competent complexes. This binding congruity indicates that in the inhibitor complexes the oxyvanadium grouping is bound at the site where (PO3-) transfer normally occurs. 31P NMR studies of the phosphate group in these complexes also provide support for this binding pattern. A number of other systems based on compounds with altered structures, such as the deoxysugar phosphates, or systems with different compositions, as in the case of the metal-free enzyme or of the glucose phosphates plus nitrate, also were examined for evidence that complexes analogous to the inhibitor complexes were formed, but none was found.(ABSTRACT TRUNCATED AT 250 WORDS)
Ray
W J
WJ
Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47907.
Burgner
J W
JW
Post
C B
CB
D019298:Glucose-6-Phosphate; D005958:Glucosephosphates / Q000378:metabolism; D008094:Lithium / Q000378:metabolism; D008274:Magnesium / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D010733:Phosphoglucomutase / Q000037:antagonists & inhibitors*; D013816:Thermodynamics; D014638:Vanadates / Q000493:pharmacokinetics*
D005958:Glucosephosphates; D014638:Vanadates; D019298:Glucose-6-Phosphate; D008094:Lithium; D010733:Phosphoglucomutase; D008274:Magnesium